Publications by authors named "Sophie D'Arcy"
Article Synopsis
- Camizestrant, an oral selective estrogen receptor degrader (SERD), shows enhanced efficacy in treating estrogen receptor-positive (ER+) breast cancer compared to existing therapies, effectively targeting resistant cancer cells.
- In preclinical studies, camizestrant demonstrated significant ER degradation and antiproliferative effects in various breast cancer models, including those resistant to current treatments like fulvestrant.
- Combining camizestrant with CDK4/6 inhibitors and PI3K/AKT/mTOR-targeted therapies increased antitumor effectiveness, suggesting a powerful approach to overcoming endocrine resistance in breast cancer patients.
